BCL6B and neoplasm: To further evaluate the predictive ability of BCL6B expression, we conducted time-dependent ROC analysis, which indicated that in both cohorts the combination of the clinical risk score (Tumor Node Metastasis (TMN) stage, histopathologic grading and preoperative alpha fetoprotein (AFP) level) and BCL6B risk score had a markedly greater contribution than did either score alone.